This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Myleran

Aspen Pharmacare Holdings Limited

Drug Names(s): Bulsufan

Description: Busulfan is a chemotherapeutic agent commonly used as part of a conditioning regimen in the transplant setting. Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a fourcarbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This produces reactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity of busulfan.

Deal Structure: In May 2009, GSK announced that it will divest eight specialist medicines to Aspen Pharmacare Holdings, including Alkeran (excluding US), Leukeran, Myleran and Purinethol.


Myleran News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug